Collaborative Arrangements and Licensing Agreements (Tables)

3 Months Ended

Mar. 31, 2019

Biogen [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the three months ended March 31, 2019 and 2018, we earned the following revenue from our relationship with Biogen (in millions, except percentage amounts):

	Three Months Ended March 31,
	2019			2018
SPINRAZA royalties (commercial revenue)	$	59.7		$	41.1
R&D revenue		24.5			10.8
Total revenue from our relationship with Biogen	$	84.2		$	51.9
Percentage of total revenue		28	%		36	%

Roche [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the three months ended March 31, 2019 and 2018, we earned the following revenue from our relationship with Roche (in millions, except percentage amounts):

	Three Months Ended March 31,
	2019			2018
R&D revenue	$	41.2		$	2.0
Percentage of total revenue		14	%		1	%

Novartis [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the three months ended March 31, 2019 and 2018, we earned the following revenue from our relationship with Novartis (in millions, except percentage amounts):

	Three Months Ended March 31,
	2019			2018
R&D revenue	$	157.1		$	17.1
Percentage of total revenue		53	%		12	%